Available online at www.ijmras.com
INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH AND STUDIES

E ISSN: 2640 -7272
Volume:08; Issue:12 (2025)

Page no.
1-12

The Clinical and Psychosocial Phenotype of Fibromyalgia Syndrome in Female Patients: A Comprehensive Review of Etiology, Burden, and Management

Dr. Eleanor V. Rhys, Prof. Amelia J. Stern

Department of Rheumatology and Pain Management, St. Jude's Medical Center, London, United Kingdom
Faculty of Health Sciences and Epidemiology, Northern University of Clinical Research, Toronto

Published Date: - 01-12-2025

ABSTRACT

Background: Fibromyalgia Syndrome (FMS) is a chronic pain disorder characterized by widespread musculoskeletal pain, fatigue, and cognitive difficulties, predominantly affecting women. Given its complex etiology and significant comorbidity profile, understanding the specific clinical and psychosocial phenotype in female patients is essential for optimized management and resource allocation.

Methods: This comprehensive review synthesizes data from peer-reviewed literature (References 1-23) focusing on the demographics, core clinical symptoms, psychological distress (e.g., anxiety, depression), functional impairment, and socioeconomic burden of FMS in female cohorts. The analysis prioritizes studies utilizing standardized assessment tools (e.g., FIQ, WHOQOL) and current diagnostic criteria.

Results: Findings confirm the high prevalence of co-morbid psychological disorders, particularly anxiety and depression, which significantly **correlate** with higher pain severity and diminished health-related quality of life (HRQoL). Functional disability is substantial, leading to high direct and indirect healthcare costs. The female phenotype is associated with specific symptom clusters that often delay diagnosis and complicate treatment.

Conclusion: FMS in female patients represents a complex, multi-dimensional burden that extends beyond physical pain. A deeper understanding of this specific phenotype is critical to developing personalized, multidisciplinary interventions that simultaneously target central sensitization, pain amplification, and associated psychological distress. Further research is required to address current diagnostic heterogeneities.

Keywords: Fibromyalgia Syndrome (FMS), Female Phenotype, Central Sensitization, Chronic Pain, Quality of Life, Psychosocial Burden, Comorbidity

INTRODUCTION

Fibromyalgia Syndrome (FMS) stands as one of the most common chronic non-inflammatory musculoskeletal pain disorders, yet it remains one of the most enigmatic conditions challenging modern medicine. It is characterized primarily by **widespread, chronic pain**, often accompanied by debilitating fatigue, sleep disturbance, and cognitive dysfunction, often referred to as "fibro fog" . The impact of FMS is profound, **affecting** an individual's physical,

psychological, and social well-being, leading to significant functional impairment.

Historically, the definition of FMS has undergone several important revisions. Initially, diagnosis was heavily reliant on the quantification of pain at specific tender points on the body. The groundbreaking work in the mid-1990s by Wolfe et al. established a key understanding of its prevalence and characteristics in the general population. More recently, the American College of Rheumatology (ACR) criteria have evolved to recognize FMS as a disorder of pain processing, shifting the focus away from tender points and towards the assessment of the Widespread Pain Index (WPI) and Symptom Severity (SS) scale, acknowledging the systemic nature of the illness. These modifications reflect a greater appreciation for the complexity of the syndrome and have improved diagnostic sensitivity.

FMS has a striking predilection for women, who are diagnosed with the condition at rates significantly higher than men, often cited as a 7:1 to 9:1 ratio. This clear **female predominance** underscores the need for research that specifically addresses the unique clinical and psychosocial characteristics observed in this majority population. Global prevalence estimates **indicate** that FMS **affects** approximately 2–4% of the population, establishing its substantial presence as a major public health concern. The burden is not just clinical; it extends to enormous societal and economic costs due to reduced work capacity and increased healthcare utilization.

Pathophysiological Mechanisms of FMS: The Neurobiological Underpinning

The key to unlocking the enigma of FMS **lies** within the central nervous system. The syndrome is not a disorder of inflammation or peripheral tissue damage but is fundamentally an issue of **impaired pain processing** and chronic nervous system dysregulation, a concept aptly summarized by the term **Central Sensitization (CS)**. CS **represents** a change in the central nervous system that enhances the feeling of pain, potentially leading to a mismatch between the nociceptive input and the resulting pain perception. This mechanism is central to understanding the female phenotype, as it **helps explain** the chronic, widespread, and disproportionate nature of the patient's suffering.

Central Sensitization and Alterations in Pain Processing: A Deep Dive into Pain Amplification

The most compelling model for FMS pain is the Central Amplification theory, rooted in demonstrable neurophysiological changes in the brain and spinal cord . Central Sensitization **involves** the potentiation of excitatory synapses within the central nervous system, effectively "turning up the volume" on pain signals. This process **may lead** to two critical clinical manifestations commonly experienced by female FMS patients:

1. **Hyperalgesia:** An exaggerated pain response to a noxious (painful) stimulus.
2. **Allodynia:** The experience of pain from a normally innocuous (non-painful) stimulus, such as light touch or temperature changes.

This amplified processing **is thought to be due to** a long-term increase in the excitability of dorsal horn neurons in the spinal cord and a profound dysregulation in descending pain control pathways emanating from the brainstem.

The Role of Nociceptive Neurotransmitters

At the molecular level, CS **is believed to be sustained** by an imbalance of key

neurotransmitters within the spinal cord and supraspinal structures. Evidence **suggests** an excessive presence of excitatory neurotransmitters combined with a deficiency in inhibitory compounds:

- **Glutamate and Substance P:** Glutamate is the primary excitatory neurotransmitter in the central nervous system. Its excessive release in the spinal cord dorsal horn **is linked** to CS . Substance P, a neuropeptide known to transmit pain signals, has been found in elevated levels in the cerebrospinal fluid of FMS patients, providing biochemical evidence for heightened nociceptive input. The over-stimulation of -methyl-D-aspartate (NMDA) receptors by glutamate **is considered** a critical step in the transition from acute pain to chronic, amplified pain states

- **Monoamine Deficiency:** Conversely, there is evidence **suggesting** a functional deficiency in the **monoaminergic inhibitory pathways**, particularly involving serotonin and norepinephrine. These neurotransmitters are crucial components of the descending pain modulatory system (DPMS), which normally acts as the body's "brake" on pain signals . The reduced function of these inhibitory circuits **may mean** that the amplified pain signals initiated in the spinal cord are allowed to propagate unchecked to the brain, **contributing** directly to the chronic, unremitting nature of FMS pain .

Functional Neuroimaging Evidence

Functional neuroimaging studies, such as functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET), have provided anatomical support for the CS model. These studies have consistently demonstrated abnormal activation patterns in the **"Pain Matrix,"** a network of brain regions involved in processing the sensory, affective, and cognitive components of pain.

- **Increased Activations:** When exposed to painful or even non-painful pressure stimuli, FMS patients show greater activation in areas responsible for sensory discrimination (e.g., the somatosensory cortex) and areas **associated** with the emotional and cognitive appraisal of pain (e.g., the insula, anterior cingulate cortex, and amygdala) compared to healthy controls. This hyper-responsivity in affective brain regions **may help explain** why the pain is often reported as emotionally distressing and consuming for female patients.

- **Reduced Inhibition:** Crucially, these studies often show reduced activity in brain regions **associated** with the DPMS, such as the periaqueductal gray (PAG) and the rostral ventromedial medulla (RVM). This finding is **consistent** with the monoamine deficiency model, **suggesting** that the brain's ability to dampen or filter pain signals is fundamentally compromised .

Dysregulation of the Descending Pain Modulatory System (DPMS)

The chronic nature of FMS pain **is thought to be related** to what is *not being suppressed* (central inhibition). The DPMS is the body’s endogenous analgesic system, working through tracts that descend from the brainstem to the spinal cord to inhibit the transmission of pain signals. In FMS, this system appears to be hypoactive or dysfunctional .

- **Conditioned Pain Modulation (CPM) Failure:** Clinical tests utilizing the paradigm of Conditioned Pain Modulation (also known as "diffuse noxious inhibitory controls," or DNIC) show that FMS patients **may be unable** to effectively inhibit pain in response to a remote, simultaneous painful stimulus. This failure of **"pain inhibits pain" is considered**

one of the strong physiological indicators of central pain processing dysregulation in FMS . This failure to engage natural analgesic mechanisms distinguishes FMS from localized chronic pain and **provides** a strong rationale for therapies that enhance central inhibition.

The Neuroendocrine-Immune Axis: The HPA and Stress

The pathophysiology **extends** beyond pure nociception to include the body's major regulatory systems, potentially linking physical symptoms to emotional vulnerability. FMS **is strongly associated** with chronic stress, psychological trauma, and affective disorders, **suggesting** a common neurobiological pathway involving the **Hypothalamic-Pituitary-Adrenal (HPA) axis** .

- **HPA Axis Dysfunction:** The HPA axis governs the body's response to stress via the release of cortisol. In FMS patients, studies often **indicate** an altered, though not always consistent, HPA axis response, typically manifesting as a blunted or hypoactive cortisol response to external stressors . This finding **may suggest** a state of chronic allostatic load, where the system has become exhausted or chronically desensitized to regulation. This endocrine dysregulation **is often considered** a critical link between life stress/trauma and the eventual emergence of FMS symptoms, particularly fatigue and sleep disturbances.
- **Implications for Sleep and Fatigue:** The chronic pain and the neuroendocrine disturbances **are thought to be** intimately linked to non-restorative sleep, a hallmark FMS symptom. Sleep is crucial for bodily repair and HPA axis regulation. The documented disturbances in slow-wave sleep in FMS patients **may prevent** the brain and body from achieving restorative rest, perpetuating fatigue and potentially exacerbating the central sensitization process, creating a self-reinforcing cycle.

Overlap with Psychiatric Disorders and the Common Pathway

The extremely high co-prevalence of FMS with psychiatric conditions, such as depression and anxiety, **is associated with** more than mere coincidence; it **suggests** a **shared biological vulnerability** driven by these central regulatory failures . FMS has even been **categorized** within the realm of psychosomatic disorders due to this tight integration of physical and psychological symptoms .

- **Shared Neurotransmitters:** The same monoamines (serotonin and norepinephrine) implicated in DPMS dysfunction are the primary targets for treating depression and anxiety. The efficacy of Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) in treating FMS pain (via enhancing the DPMS) and in treating MDD (via mood elevation) **points** to a unifying neurochemical substrate . The chronic stress and endocrine dysregulation that **contribute** to FMS symptoms are also known to be powerful precursors to depressive episodes.
- **Clinical Implications:** Recognizing the neurobiological overlap **validates** the use of combined pharmacological and psychological therapies, particularly **Cognitive Behavioral Therapy (CBT)**, as core components of a multidisciplinary management strategy . CBT aims to modify catastrophic thinking and fear-avoidance behaviors that further activate stress circuits and amplify pain perception, effectively retraining the central nervous system.

This detailed exploration of the neurobiological underpinnings **confirms** that the complex

clinical and psychosocial phenotype of the female FMS patient **is rooted** in a highly sensitized central nervous system and dysfunctional pain inhibition. This understanding **is paramount** for shifting the diagnostic and therapeutic focus toward centrally-acting mechanisms rather than peripheral tissues.

Rationale and Literature Gap

Despite decades of research, significant challenges persist in the consistent diagnosis and effective management of FMS . A primary issue **is** the lack of a definitive, objective biomarker, **leading** to diagnoses often based on subjective symptom reports and clinical exclusion . The frequent co-occurrence of FMS with other conditions, particularly psychiatric ones, further complicates the clinical picture .

Literature Gap to be Addressed

While the foundational characteristics of FMS are well-documented, a comprehensive, synthesized understanding of the combined **clinical, psychosocial, and economic burden** that defines the *female* phenotype **remains** fragmented. Much of the literature **touches** upon these aspects individually, but a unified review detailing how the constellation of pain, cognitive dysfunction, psychiatric comorbidity, and functional impairment synergistically **contributes** to disability and high healthcare utilization in this dominant patient group **is needed**. This article seeks to provide this cohesive synthesis, grounding the complex experience of FMS within the female patient perspective to guide future research and personalized care strategies.

Study Aims and Objectives

The primary objective of this article is to comprehensively synthesize the current evidence detailing the clinical and psychosocial phenotype of female patients with FMS. The secondary objectives include:

1. To detail the core clinical characteristics, including pain severity and associated somatic symptoms.
2. To analyze the prevalence and impact of psychological distress and functional impairment.
3. To quantify the socioeconomic burden and healthcare utilization **associated with** FMS in this patient population.
4. To identify key gaps in the current literature to inform future research priorities.

Methods

Study Design and Scope

This study constitutes a comprehensive narrative review, drawing upon the provided reference list to synthesize established findings on the clinical characteristics, associated conditions, and overall burden of FMS, with a specific focus on studies involving female patients. The scope **is designed** to provide an expansive, integrated perspective suitable for an in-depth, long-form academic publication.

Inclusion and Exclusion Criteria

The included references cover key areas such as FMS etiology and pathogenesis, neurobiology and central sensitization, diagnostic criteria, psychiatric comorbidity, quality of life and

functional assessmen , and health economic evaluations. The focus **is maintained** on findings that are particularly relevant to the predominantly female FMS population.

Search Strategy and Data Sources

The primary source for all information and citations is the **23-item reference list** provided by the authors. No external sources or citations beyond this list are used, **strictly adhering** to the citation constraint (maximum citation number 23). The structure of this paper **reflects** a deep analytical reading and synthesis of the arguments, findings, and conclusions presented across these core references.

Data Extraction and Analysis

Information was systematically extracted from the source material, focusing on the following key domains:

- **Clinical:** Definitions, diagnostic criteria, somatic symptoms (e.g., pain, fatigue, sleep disturbance).
- **Psychological:** Prevalence of anxiety, depression, and other psychiatric disorders.
- **Functional/Quality of Life (QoL):** Assessment metrics used (e.g., FIQ, WHOQOL), and reported QoL outcomes.
- **Socioeconomic:** Healthcare costs (direct/indirect), disability, and work impairment.

The data extracted **allows** for a thematic analysis, synthesizing quantitative data (e.g., prevalence rates, cost figures) with qualitative insights (e.g., descriptions of FMS as a disorder of pain processing) to build a holistic picture of the female FMS phenotype.

Quality Assessment

Given that this **is** a narrative review based on a fixed reference list, formal risk of bias assessment using external tools **is not applicable**. Instead, the quality and relevance of the findings **were implicitly evaluated** based on the academic standing of the journals and the topical focus of the included literature, **ensuring** the synthesized results are grounded in established rheumatology and pain research.

Results

Demographic and Core Clinical Characteristics

The FMS patient population **is overwhelmingly female**, and this demographic reality significantly **shapes** the clinical picture . The typical patient **is diagnosed** during middle age, often after a long and frustrating journey seeking a diagnosis, a process exacerbated by the non-specific and fluctuating nature of symptoms .

Age of Onset, Time to Diagnosis, and Co-morbidities

While the mean age of onset **varies**, a considerable number of women **begin** experiencing symptoms in their 30s and 40s, with diagnosis often delayed by several years . The pain **is described** as widespread and chronic, but critically, it **is accompanied** by a constellation of **non-pain somatic symptoms**. These comorbidities **are integral** to the syndrome and significantly **contribute** to the overall burden . These commonly include:

- Chronic fatigue and non-restorative sleep.
- Irritable Bowel Syndrome (IBS).
- Chronic headaches/migraines.
- Restless Legs Syndrome.
- Cognitive difficulties ("fibro fog").

Detailed Analysis of Pain Severity, Location, and Chronicity

The hallmark of FMS **is** the persistent, widespread pain . This pain **is often described** as deep aching, burning, or throbbing. The application of diagnostic tools like the WPI **assesses** the extent of this widespread pain, which, combined with the SS scale, **quantifies** the severity of core symptoms (fatigue, waking unrefreshed, and cognitive problems) . The severity of this chronic pain **is directly linked** to functional outcome; women reporting higher pain indices frequently **exhibit** lower quality of life and greater disability, establishing pain as the dominant clinical driver of impairment .

Psychosocial and Functional Impairment

The interface between physical pain and psychological distress **is** a defining characteristic of FMS, especially within the female patient cohort. The chronic, unrelenting nature of the pain and the lack of visible pathology often **is associated with** significant mental health challenges.

Prevalence and Impact of Psychological Distress

Psychiatric disorders, particularly **Major Depressive Disorder (MDD) and various anxiety disorders**, **are** highly prevalent in FMS patients . Studies **indicate** that a significant percentage of patients meet the criteria for these conditions, with some estimates **suggesting** lifetime prevalence of MDD reaching 60–80% . The relationship between FMS and psychological distress **is complex** and bidirectional:

- Chronic pain **is** a known trigger for anxiety and depression .
- Pre-existing psychological vulnerability **may be associated with** lower the pain threshold and increase the perception of pain, **contributing** to the central sensitization phenomenon.
- Higher levels of anxiety and depression **are consistently associated with** higher self-reported FMS severity and worse functional outcomes .

This symbiotic relationship **highlights** why FMS **is often conceptualized** as a psychosomatic disorder requiring integrated treatment approaches .

Evaluation of Sleep Disturbance and Fatigue as Core Symptoms

Alongside pain, **fatigue** and **non-restorative sleep are** the most common and disruptive symptoms, often ranked by patients as more debilitating than the pain itself . Sleep disturbance **is characterized** by frequent awakenings and an inability to achieve deep, slow-wave sleep. This chronic sleep deficit **contributes** directly to persistent fatigue, reduced energy, and **exacerbates** the cognitive symptoms (fibro fog), creating a debilitating cycle of pain, poor sleep, and reduced function.

Quality of Life (QoL) and Functional Status Assessment

Health-Related Quality of Life (HRQoL) **is severely impaired** in women with FMS . Standardized instruments **are crucial** for quantifying this impact:

- **Fibromyalgia Impact Questionnaire (FIQ):** This tool **is widely used** to measure the overall impact of FMS, **assessing** physical function, work status, pain, fatigue, and other symptoms . Studies using the FIQ consistently **show** a high level of disease severity and functional disability.
- **WHOQOL:** The World Health Organization Quality of Life assessment **highlights** deficits across physical health, psychological well-being, social relationships, and environment domains, **confirming** FMS **affects** every aspect of life .

The consistent finding across these measures **is** that physical symptoms (pain and fatigue) and psychological symptoms (anxiety and depression) **are** the strongest predictors of poor QoL in female FMS patients .

Socioeconomic Burden and Disability

The chronic nature and associated disability of FMS **translate** directly into a massive socioeconomic burden for patients, healthcare systems, and society at large.

Impact on Employment, Work Productivity, and Disability Rates

FMS severely **compromises** a woman's ability to maintain employment and function effectively in the workplace. The debilitating fatigue, pain, and "fibro fog" often **lead** to reduced productivity (presenteeism) or, more frequently, total absence from work (absenteeism) . Disability rates **are high**; FMS patients **are significantly more likely** to apply for and receive disability benefits than the general population, **representing** a major loss of human capital and economic strain .

Direct and Indirect Healthcare Costs Associated with FMS Management

The financial burden of FMS **is substantial**. **Direct costs include** expenses related to frequent physician visits, specialized consultations (rheumatology, neurology, psychology), diagnostic tests (often ruling out other conditions), and polypharmacy (medications for pain, sleep, and mood) . **Indirect costs**, which often **exceed** direct costs, **stem** from productivity losses, early retirement, and long-term disability . Studies across various countries consistently **demonstrate** that FMS patients **generate significantly higher healthcare costs** compared to matched controls, making it a condition of major economic concern . Early and accurate diagnosis, as well as effective management, **is crucial** to potentially mitigate some of these escalating long-term costs .

Gender-Specific Differences in Symptom Presentation

While the majority of research **focuses** on the female experience, gender differences **have been noted**. Female patients consistently **report** higher pain levels and more widespread symptoms than their male counterparts . They also **report** a higher prevalence of **associated** conditions like tension headaches and IBS. This **suggests** that the same underlying central sensitization mechanism **may manifest** with greater symptom intensity and a broader range of clinical expressions in women, emphasizing the importance of dedicated research into the female phenotype.

Discussion

Synthesis of Key Findings

The data synthesized from the provided literature **paints** a clear picture: Fibromyalgia Syndrome, particularly in the female patient population, **is** a pervasive, multi-system disorder driven by neurobiological alterations, **resulting** in an amplified pain experience and severe functional compromise. The core characteristics—**chronic widespread pain, debilitating fatigue, and non-restorative sleep**—do not occur in isolation. Instead, they **are believed to operate** synergistically with high rates of psychological comorbidity (anxiety and depression) to precipitate a profound reduction in HRQoL and functional capacity . The chronic stress and lack of coping mechanisms **resulting** from the disease **may contribute** to the persistence of symptoms and disability, **reinforcing** the need to address the central neurobiological and psychological mechanisms concurrently.

Implications for Diagnosis and Management

The findings strongly **support** the modern understanding of FMS as a disorder of pain processing, **necessitating** a paradigm shift away from purely musculoskeletal treatments.

Discussion of Current Evidence-Based Guidelines for Diagnosis and Therapy

Current guidelines **advocate** for a diagnosis that **incorporates** both the subjective experience of pain and associated symptoms (WPI and SS scores) . The failure to recognize the accompanying symptoms, such as fatigue and cognitive disturbance, often **leads** to missed or delayed diagnosis. Furthermore, effective management **must be multidisciplinary** . Pharmacological treatments **targeting** the central nervous system (e.g., centrally-acting analgesics, antidepressants) **are often combined** with non-pharmacological interventions, **including** patient education, exercise, and cognitive behavioral therapy (CBT) . The success of treatment **is measured** not just by a reduction in pain but by improvements in functional status and quality of life .

The Necessity for a Multidisciplinary, Patient-Centered Approach

Given the strong **association** between pain severity and psychological factors, a treatment plan that **fails** to address anxiety and depression **is fundamentally incomplete** . A patient-centered approach that **integrates** rheumatologists, pain specialists, physiotherapists, and psychologists **is essential**. This integrated care model **acknowledges** the psychosomatic nature of the disorder and **is critical** for helping patients manage the disease's long-term physical and mental impact

Future Research Directions

Despite significant progress in understanding the neurobiology of FMS, several critical areas **require** further investigation:

Need for Robust, Large-Scale Studies on Novel Biomarkers

The persistent lack of an objective diagnostic marker **remains** a substantial barrier to timely and confident diagnosis. Future research **must focus** on identifying reliable, gender-specific biological markers—whether genetic, neuroimaging, or immunological—that **could complement** the clinical criteria and validate the subjective patient experience.

Exploring the Efficacy of Targeted, Gender-Specific Interventions

Since the vast majority of patients **are female**, future therapeutic trials should specifically **investigate** interventions (e.g., pain medication dosages, hormonal therapies, or exercise protocols) that **might be uniquely effective** for women, potentially driven by hormonal differences in pain perception.

Improving Validation of Health Economic Models and Long-term Cost Studies

While the economic burden **is established**, more granular studies **are needed** to quantify the cost-effectiveness of various multidisciplinary management strategies over the long term. Demonstrating that comprehensive, early intervention **is associated with reduced** indirect costs (disability, absenteeism) **could serve** as a powerful argument for increased healthcare funding and resource allocation for FMS patients.

Limitations of the Current Study/Review

While comprehensive, this review **is subject** to several inherent limitations.

Limitation Example 1: Reliance on Varied Diagnostic Criteri

The synthesized literature **spans** multiple decades, **utilizing** different versions of the ACR diagnostic criteria (e.g., 1990 criteria versus the 2010 modified criteria) . This heterogeneity in diagnostic standards across the included studies **may influence** reported prevalence rates and the characteristics of the cohorts analyzed, **making** direct comparison challenging.

Limitation Example 2: Subjectivity and Heterogeneity of FMS

FMS symptoms **are inherently subjective** and widely heterogeneous among patients. Standardizing the assessment of chronic pain, fatigue, and cognitive dysfunction for objective analysis **remains** a major challenge. The reliance on patient self-report tools, while necessary, **introduces** potential biases into the data.

Limitation Example 3: Potential Publication Bias

As with any review, there **is** a potential for publication bias, where studies **showing** significant or positive findings (e.g., higher comorbidity rates or positive treatment effects) **are more likely** to be published than those with null results

Conclusion

Fibromyalgia Syndrome **is** a highly impactful chronic condition defined by central nervous system dysregulation, **manifesting** as a severe, multi-symptom phenotype primarily in women. The synthesis of evidence **confirms** the intertwined nature of physical symptoms, psychological distress, and functional impairment, **culminating** in a significant socioeconomic burden. The future of FMS management **hinges** on recognizing this complexity through validated biomarkers and implementing truly multidisciplinary, patient-centered care models.

References

1. Bellato E, Marini E, Castoldi F, Barbasetti N, Mattei L, Bonasia DE, et al. Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. Pain Res Treat. 2012;2012:426130. doi: 10.1155/2012/426130.

2. Clauw DJ. Fibromyalgia: an overview. Am J Med. 2009;122(12 Suppl):S3-S13. doi: 10.1016/j.amjmed.2009.09.006.

3. Pagano T, Matsutani LA, Ferreira EA, Marques AP, Pereira CA. Assessment of anxiety and quality of life in fibromyalgia patients. Sao Paulo Med J. 2004;122(6):252-8. doi: 10.1590/s1516-31802004000600005.

4. Price DD, Staud R. Neurobiology of fibromyalgia syndrome. J Rheumatol Suppl. 2005;75:22-8. PMID: 16078357.

5. Petersel DL, Dror V, Cheung R. Central amplification and fibromyalgia: disorder of pain processing. J Neurosci Res.2011;89(1):29-34. doi: 10.1002/jnr.22512.

6. Häuser W, Burgmer M, Köllner V, Schaefert R, Eich W, Hausteiner-Wiehle C, et al. [Fibromyalgia syndrome as a psychosomatic disorder - diagnosis and therapy according to current evidence-based guidelines]. Z Psychosom Med Psychother. 2013;59(2):132-52. doi: 10.13109/zptm.2013.59.2.132.

7. Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med. 2007;146(10):726-34. doi: 10.7326/0003-4819-146-10-200705150-00006.

8. Epstein SA, Kay G, Clauw D, Heaton R, Klein D, Krupp L, et al. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics. 1999;40(1):57-63. doi: 10.1016/s0033-3182(99)71272-7.

9. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41(10):1403-9. doi: 10.1016/0277-9536(95)00112-k.

10. Campos RP, Vázquez MIR. Health-related quality of life in women with fibromyalgia: clinical and psychological factors associated. Clin Rheumatol. 2012;31:347-55. doi: 10.1007/s10067-011-1870-7.

11. Sezgin Özcan D, Aras M, Köseoğlu BF, Şentürk Güven Ş. Quality of life and associated conditions in women with fibromyalgia syndrome. Osteoporoz. 2013;19:0-0. doi: 10.4274/tod.38258

12. Vincent A, Lahr BD, Wolfe F, Clauw DJ, Whipple MO, Oh TH, et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken).2013;65(5):786-92. doi: 10.1002/acr.21896.

13. Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract. 2007;61(9):1498-508. doi: 10.1111/j.1742-1241.2007.01480.x.

14. Lamotte M, Maugars Y, Le Lay K, Taïeb C. Health economic evaluation of outpatient management of fibromyalgia patients and the costs avoided by diagnosing fibromyalgia in France. Clin Exp Rheumatol. 2010;28(6 Suppl):S64-S70.

15. Grodman I, Buskila D, Arnson Y, Altaman A, Amital D, Amital H. Understanding fibromyalgia and its resultant disability. IMAJ-Israel Med Assoc J. 2011;13(12):769. PMID: 22332450.

16. D'Onghia M, Ciaffi J, Ruscitti P, Cipriani P, Giacomelli R, Ablin JN, Ursini F. The economic

burden of fibromyalgia: A systematic literature review. Semin Arthritis Rheum. 2022;56:152060. doi: 10.1016/j.semarthrit.2022.152060.

17. Nguyen VC, Park J. Relationships between demographic factors and chronic conditions with disease severities. Int J Environ Res Public Health. 2021;18(21):11469. doi: 10.3390/ijerph182111469.

18. Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int. 2000;20(1):9-12. doi: 10.1007/s002960000077.

19. Bennett RM, Friend R, Marcus D, Bernstein C, Han BK, Yachoui R, et al. Criteria for the diagnosis of fibromyalgia: validation of the modified 2010 preliminary American College of Rheumatology criteria and the development of alternative criteria. Arthritis Care Re[1]s (Hoboken). 2014;66:1364-73. doi: 10.1002/acr.22301.

20. Dernek B. Fibromiyalji Sendromu Hastalarının İşlevsellik, Yetiyitimi ve Sağlığın Uluslararası Sınıflandırılması ICF Kapsamında Değerlendirilmesi: Pilot Çalışma. Acıbadem Univ Health Sci J. 2020;1:160-6.

21. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19-28.

22. Cacace E, Ruggiero V, Anedda C, Denotti A, Minerba L, Perpignano G. Quality of life and associated clinical distress in fibromyalgia. Reumatismo. 2006/09/30;58. doi: 10.4081/reumatismo.2006.226.

23. Aparicio VA, Ortega FB, Carbonell-Baeza A, Cuevas AM, Delgado-Fernández M, Jonatan R. Anxiety, depression and fibromyalgia pain and severity. Behav Psychol. 2013;21:381